Thirteen WGs of the Network are engaged in different neoplastic types and clinical research with the aim of quickly bringing personalized medicine of excellence in national oncology.
In ACC are active thirteen Working Groups committed to different types of neoplastic (Colon, Breast, Lung, Glioblastoma, Melanoma, Sarcoma and Tumors of the musculoskeletal apparatus) and clinical research (Genomics, Pathological Anatomy and Biobanks, Oncohematology, Immunotherapy, Radiomics and Survivorship care and nutritional support). Furthermore, the optimization of using new drugs for each cancer pathology is among the other tasks of the WGs.
The opportunity offered by the genomic characterization of tumours, the core of ACC activities, must be exploited in the clinical setting. For this to happen – and the Network is working in this direction – it is necessary to allow patients of associated IRCCS to participate in targeted and better quality clinical trials through the appropriate use of innovative drugs administered only after accurate characterization of predictive biomarkers.
The objective is to bring personalized medicine of excellence in national oncology quickly, with the potential to reduce pharmaceutical spending through a substantial increase in the appropriate use of new drugs.
Conversion of non-responsive patients into responsive with development of new combined therapiesFind out
Survivorship Care and Nutritional Support
Alongside recovered patients, chronic and long-term cancer survivorsFind out